Edward P. Harvey

Edward P. Harvey

Auto-generated profile, based on publicly available information

Edward P. Harvey

Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Cell Chemical Biology
Verified
Journal Article
Closed access
AHAnnissa J. Huhn
Annissa J. Huhn
RGRachel M. Guerra
Rachel M. Guerra
EHEdward P. Harvey
Edward P. Harvey
GBGregory H. Bird
Gregory H. Bird
LWLoren D. Walensky
Loren D. Walensky

1 January 2018 in Structure
Verified
Journal Article
Closed access
EHEdward P. Harvey
Edward P. Harvey
HSHyuk-Soo Seo
Hyuk-Soo Seo
RGRachel M. Guerra
Rachel M. Guerra
GBGregory H. Bird
Gregory H. Bird
SDSirano Dhe-Paganon
Sirano Dhe-Paganon
LWLoren D. Walensky
Loren D. Walensky

1 September 2018 in Cell Reports
Verified
Journal Article
Open access
RGRachel M. Guerra
Rachel M. Guerra
GBGregory H. Bird
Gregory H. Bird
EHEdward P. Harvey
Edward P. Harvey
NDNeekesh V. Dharia
Neekesh V. Dharia
KKKyle J. Korshavn
Kyle J. Korshavn
LWLoren D. Walensky
Loren D. Walensky
Cancer cells overexpress a diversity of anti-apoptotic BCL-2 family proteins, such as BCL-2, MCL-1, and BFL-1/A1, to enforce cellular immortality. Thus, intensive drug development efforts have focused on targeting this class of oncogenic proteins to overcome treatment resistance. Whereas a selective BCL-2 inhibitor has been FDA approved and several small molecule inhibitors of MCL-1 have recently entered phase I clinical testing, BFL-1/A1 remains undrugged. Here, we developed a series of stapled peptide design principles to engineer a functionally selective and cell-permeable BFL-1/A1 inhibitor that is specifically cytotoxic to BFL-1/A1-dependent human cancer cells. Because cancers harbor a diversity of resistance mechanisms and typically require multi-agent treatment, we further investigated BFL-1/A1 co-dependencies by mining a genome-scale CRISPR-Cas9 screen. We identified ataxia-telangiectasia-mutated (ATM) kinase as a BFL-1/A1 co-dependency in acute myeloid leukemia (AML), which informed the validation of BFL-1/A1 and ATM inhibitor co-treatment as a synergistic approach to subverting apoptotic resistance in cancer.

10 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJeffrey S Smith
Jeffrey S Smith
JHJoseph D. Hurley
Joseph D. Hurley
AGAlyana Granados
Alyana Granados
ESErnst W. Schmid
Ernst W. Schmid
KSKatherine J. Susa
Katherine J. Susa
Antibodies are central mediators of the adaptive immune response, and they are powerful research tools and therapeutics. Antibody discovery requires substantial experimental effort, such as immunization campaigns or in vitro library screening. Predicting antibody-antigen binding a priori remains challenging. However, recent machine learning methods raise the possibility of in silico antibody discovery, bypassing or reducing initial experimental bottlenecks. Here, we report a virtual screen using AlphaFold-Multimer (AF-M) that prospectively identified nanobody binders to MRGPRX2, a G protein-coupled receptor (GPCR) and therapeutic target for the treatment of pseudoallergic inflammation and itch. Using previously reported nanobody-GPCR structures, we identified a set of AF-M outputs that effectively discriminate between interacting and non-interacting nanobody-GPCR pairs. We used these outputs to perform a prospective in silico screen, identified nanobodies that bind MRGPRX2 with high affinity, and confirmed activity in signaling and functional cellular assays. Our results provide a proof of concept for fully computational antibody discovery pipelines that can circumvent laboratory experiments.

12 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SPSteffanie Paul
Steffanie Paul
EHEdward P. Harvey
Edward P. Harvey
JOJames Osei-Owusu
James Osei-Owusu
AKAaron W. Kollasch
Aaron W. Kollasch
ARAdam J. Riesselman
Adam J. Riesselman
AKAndrew C. Kruse
Andrew C. Kruse
Antibodies can bind their targets with exquisite potency and selectivity due in part to large antibody-target protein-protein interaction surface areas. Despite the very large size and diversity of synthetic libraries, in vitro sorting alone tends to yield binders with modest affinities. By analogy to the in vivo affinity maturation in the natural immune system, these initial hits are typically affinity matured in vitro to achieve high affinity binding. However, affinity maturation campaigns can be laborious, often requiring multiple selection rounds and strategies for each clone to be optimized. Here, we investigated whether one could accelerate the discovery of optimized binders using machine learning on sequencing data from single selection sorts of affinity maturation yeast-display campaigns. Our results show that sparse sequencing data from a single sorting round can predict sequences that are enriched after multiple rounds. We also find that linear models outperform deep neural networks and semi-supervised approaches in ranking validated affinity-enhancing substitutions. Linear models are also more interpretable, offering insights into residue preferences that can be leveraged for further engineering. We use our models to design and select optimized nanobody binders to relaxin family peptide receptor 1 (RXFP1), yielding multiple improved binders including 3 sub nanomolar binders with the best exhibiting a ∼2500-fold improvement over WT.

13 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJung-Eun Shin
Jung-Eun Shin
MSMeredith A. Skiba
Meredith A. Skiba
GNGenevieve R. Nemeth
Genevieve R. Nemeth
JHJoseph D. Hurley
Joseph D. Hurley
AKAndrew C. Kruse
Andrew C. Kruse
Antibodies are essential biological research tools and important therapeutic agents, but some exhibit non-specific binding to off-target proteins and other biomolecules. Such polyreactive antibodies compromise screening pipelines, lead to incorrect and irreproducible experimental results, and are generally intractable for clinical development. We designed a set of experiments using a diverse naïve synthetic camelid antibody fragment (‘nanobody’) library to enable machine learning models to accurately assess polyreactivity from protein sequence (AUC > 0.8). Moreover, our models provide quantitative scoring metrics that predict the effect of amino acid substitutions on polyreactivity. We experimentally tested our model’s performance on three independent nanobody scaffolds, where over 90% of predicted substitutions successfully reduced polyreactivity. Importantly, the model allowed us to diminish the polyreactivity of an angiotensin II type I receptor antagonist nanobody, without compromising its pharmacological properties. We provide a companion web-server that offers a straightforward means of predicting polyreactivity and polyreactivity-reducing mutations for any given nanobody sequence.